ROKIT America, Inc.

S-1/A amended

Price $9.50 · Range $8.50 to $10.50 · 2,631,579 shares · Gross proceeds $25,000,000

ROKIT America, Inc. is conducting its initial public offering (IPO) of 2,631,579 shares of common stock at an estimated price range of $8.50 to $10.50 per share, with a midpoint of $9.50. The offering includes underwriter warrants and an over-allotment option. The company aims to list on Nasdaq under the symbol 'RKAM' and emphasizes its focus on dietary supplements and regenerative medicine technologies, including its Reverse Aging Product (RAP) and Organ Regeneration Platform (ORP).

S-1 filed

ROKIT America, Inc. is conducting its initial public offering (IPO) of common stock, aiming to list on Nasdaq under the symbol 'RKAM'. The company focuses on developing a Reverse Aging Product (RAP) for cellular health and an AI-driven Organ Regeneration Platform (ORP) for regenerative medicine. The ORP includes 3D bioprinting, AI wound modeling, and autologous bioinks, with early revenue generation in the Americas. The IPO is contingent on listing approval, and the company has granted underwriters an option to purchase additional shares.

DRS/A amended

ROKIT America, Inc. is conducting its initial public offering (IPO) of common stock, aiming to list on Nasdaq under the symbol 'RKAM'. The company focuses on dietary supplements centered around NMN and fisetin, alongside developing proprietary regenerative medicine technologies like the Organ Regeneration Platform (ORP). The offering is contingent on Nasdaq approval, with underwriters including Maxim Group LLC. The company emphasizes its expansion into patented technologies and partnerships with its parent entity, ROKIT Healthcare.

DRS/A amended

ROKIT America, Inc. is conducting its initial public offering (IPO) of common stock, with no existing public market. The company focuses on dietary supplements like NMN and RAP, along with AI-driven regenerative medicine platforms. The offering is contingent on Nasdaq listing approval, with an anticipated price range. The company is an emerging growth and smaller reporting company, leveraging reduced reporting requirements.

DRS/A amended

ROKIT America, Inc. is conducting its initial public offering (IPO) of common stock, with no existing public market for its shares. The company, an emerging growth and smaller reporting company, aims to list on Nasdaq under the symbol 'RKAM.' The offering includes its Reverse Aging Product (RAP) and Organ Regeneration Platform (ORP), focusing on dietary supplements and regenerative medicine. The filing emphasizes risks related to market competitiveness, regulatory uncertainties, and reliance on its parent company, ROKIT Healthcare.

DRS filed

ROKIT America, Inc. is conducting its initial public offering (IPO) of common stock, seeking to list on Nasdaq under the symbol 'RKAM.' The company, an emerging growth company, focuses on developing anti-aging and regenerative healthcare solutions through its Reverse Aging Platform (RAP) and Organ Regeneration Platform (ORP), licensed from its parent entity, ROKIT Healthcare. The offering lacks a public market for its stock, and the company anticipates an IPO price range and relies on its intellectual property and partnerships for growth.